| Treatment of gastric cancer M Orditura, G Galizia, V Sforza, V Gambardella, A Fabozzi, MM Laterza, ... World journal of gastroenterology: WJG 20 (7), 1635, 2014 | 788 | 2014 |
| Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy E Martinelli, R De Palma, M Orditura, F De Vita, F Ciardiello Clinical & Experimental Immunology 158 (1), 1-9, 2009 | 398 | 2009 |
| A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients F De Vita, M Orditura, E Matano, R Bianco, C Carlomagno, S Infusino, ... British journal of cancer 92 (9), 1644-1649, 2005 | 352 | 2005 |
| Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer … E Lieto, F Ferraraccio, M Orditura, P Castellano, AL Mura, M Pinto, ... Annals of surgical oncology 15, 69-79, 2008 | 343 | 2008 |
| Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery G Galizia, M Orditura, C Romano, E Lieto, P Castellano, L Pelosio, ... Clinical immunology 102 (2), 169-178, 2002 | 273 | 2002 |
| Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery G Galizia, E Lieto, M Orditura, P Castellano, AL Mura, V Imperatore, ... World journal of surgery 31 (7), 1458-1468, 2007 | 210 | 2007 |
| Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer G Galizia, E Lieto, F De Vita, M Orditura, P Castellano, T Troiani, ... Oncogene 26 (25), 3654-3660, 2007 | 200 | 2007 |
| Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients F De Vita, M Orditura, G Galizia, C Romano, A Roscigno, E Lieto, ... Chest 117 (2), 365-373, 2000 | 196 | 2000 |
| PARP inhibitors in ovarian cancer E Franzese, S Centonze, A Diana, F Carlino, LP Guerrera, M Di Napoli, ... Cancer Treatment Reviews 73, 1-9, 2019 | 186 | 2019 |
| Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase … S Pignata, D Lorusso, G Scambia, D Sambataro, S Tamberi, S Cinieri, ... The Lancet Oncology 16 (5), 561-568, 2015 | 170 | 2015 |
| Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery G Galizia, E Lieto, F Ferraraccio, F De Vita, P Castellano, M Orditura, ... Annals of surgical oncology 13, 823-835, 2006 | 169 | 2006 |
| Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma F De Vita, M Orditura, E Lieto, S Infusino, F Morgillo, E Martinelli, ... Cancer 100 (2), 270-278, 2004 | 163 | 2004 |
| Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study G Galizia, E Lieto, F De Vita, F Ferraraccio, A Zamboli, A Mabilia, ... International journal of colorectal disease 29, 89-97, 2014 | 160 | 2014 |
| First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases G Galizia, E Lieto, M Orditura, P Castellano, V Imperatore, M Pinto, ... Archives of Surgery 143 (4), 352-358, 2008 | 159 | 2008 |
| Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors MP Morelli, T Cascone, T Troiani, F De Vita, M Orditura, G Laus, ... Annals of Oncology 16, iv61-iv68, 2005 | 159 | 2005 |
| Targeting EGFR in pancreatic cancer treatment T Troiani, E Martinelli, A Capasso, F Morgillo, M Orditura, F De Vita, ... Current drug targets 13 (6), 802-810, 2012 | 152 | 2012 |
| Determination of molecular marker expression can predict clinical outcome in colon carcinomas G Galizia, E Lieto, F Ferraraccio, M Orditura, F De Vita, P Castellano, ... Clinical cancer research 10 (10), 3490-3499, 2004 | 152 | 2004 |
| The role of EGFR inhibitors in nonsmall cell lung cancer F Ciardiello, F De Vita, M Orditura, G Tortora Current opinion in oncology 16 (2), 130-135, 2004 | 146 | 2004 |
| Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy F Ciardiello, T Troiani, R Bianco, M Orditura, F Morgillo, E Martinelli, ... Annals of Oncology 17, vii109-vii114, 2006 | 141 | 2006 |
| Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines F Morgillo, FC Sasso, CM Della Corte, D Vitagliano, E D'Aiuto, T Troiani, ... Clinical Cancer Research 19 (13), 3508-3519, 2013 | 137 | 2013 |
